{"id":728180,"date":"2023-02-02T08:17:22","date_gmt":"2023-02-02T13:17:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/"},"modified":"2023-02-02T08:17:22","modified_gmt":"2023-02-02T13:17:22","slug":"gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/","title":{"rendered":"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences"},"content":{"rendered":"<h2>\nGain to present new preclinical data on its lead programs in GBA1-related diseases<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">BETHESDA, Md., Feb.  02, 2023  (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present new preclinical data at the following upcoming scientific and medical meetings.<\/p>\n<p align=\"justify\">\u201cThe body of data that has been generated over the past year in our lead program for GBA1-related diseases is impressive as it demonstrates the mechanism of action and the potentially disease-modifying effect in multiple relevant <em>in vitro<\/em> and <em>in vivo<\/em> models,\u201d said Matthias Alder, CEO of Gain Therapeutics. \u201cBased on these data, we look forward to starting the clinical stage development with our drug candidate GT-02287 later this year.\u201d<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i_L1VtZVSwTX78q-52XTKK_RW4SaxdH4S_P4thVEnI6I8-CTaJCGnsuSDIf8WORPNEFwpu-uSnigk_HcgW2xlXV98_JTNYg47H5qmI64ePw=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>19th Annual WORLDSymposium<br \/><\/strong><br \/>\n        <\/a><br \/>\n        <strong>Website: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YcHnK2BECU5ZPuwsMTGYJZL7wtK_CVXXAyMXdJHuOungm9jfsn2iYrRihYaLh2xg5aM18ifR_tzux7U0YgmUZnJ_pvVoi9lly3Zm24humU0=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/worldsymposia.org<\/a><br \/>\n        <br \/>\n        <strong>Location: <\/strong>Orlando, FL, USA<br \/><strong>Date\/Time:<\/strong> February 22 \u2013 26, 2023<br \/><strong>Presenter: <\/strong>Beatriz Calvo-Flores Guzman, Ph.D., Gain Therapeutics<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7RxK37grNA_v2k8x1t57yIn2kIgFt7o2oamOaB1um2bvMN8weKm7kKz4Qvl9VDOtfA1vjGddUbDobXXTgO1gbbHsC6JSoftH32du25PcmeqX_NLBgeO9NWxTvfDjxeRPjPxpp9pCXf1H3VTxTFSIuIiGestFssTj3JwHlAL-3MU7fQ8hl7mNP1g2k9OoZo4_\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>AD\/PD 23: 17th International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases<br \/><\/strong><br \/>\n        <\/a><br \/>\n        <strong>Website: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YcHnK2BECU5ZPuwsMTGYJUbmYGEciGq9gXYFPoin49Ld1EAp0ctN_1n2DfRz9Cq21-N0GcbDUfmgv4yZZawuGCyTRVkPogD20W35CnaBwXw=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/adpd.kenes.com<\/a><br \/>\n        <br \/>\n        <strong>Date\/Time:<\/strong>\u00a0March 28 \u2013 April 1, 2023<br \/><strong>Location:<\/strong> Gothenburg, Sweden<br \/><strong>Presenter:<\/strong> Beatriz Calvo-Flores Guzman, Ph.D., Gain Therapeutics<\/p>\n<p>\n        <strong><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lr9z96U8QhNQQaVPPFHPOdLiwL26yPvAlM6y4IrR9A34XieDpdXQ34tK1FH1bbsm4duiN3SZqPjNTpNcOpnuRcpjc8jAgm7r2icpK09HP4OrrPyjtFSjWbTxOcgQC4R82V4n_OOrHcnKWSSG2Rl4-QVkveymUd5sbwm1C7Et0lw=\" rel=\"nofollow noopener\" target=\"_blank\">19th Orphan Drugs &amp; Rare Diseases Global Congress 2023 Europe<\/a><br \/>\n          <br \/>Website:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YcHnK2BECU5ZPuwsMTGYJT95RhKDVfR4xhU95yOFEwLImZBN0XNT81jIA6pSxKqbTgOrYEpISDQuGcomoT11LEiQQmyNHSyel5-Dpp3YLi74-5LAdwHmTgYHy7nXudhL\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.orphandrugscongress.com<\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CSWq-Scyl2CVigWIU8PlEy2FplsJpoEU1IZura3GBIt2mEgGMS_E7a-4kdr4Z_cBcUDAH4HUyJncb2lCDZgtgw==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <br \/>\n        <\/a><br \/>\n        <strong>Date\/Time:\u00a0<\/strong>April 3 &#8211; 4, 2023<br \/><strong>Location:<\/strong> London, UK<br \/><strong>Presenter:<\/strong> Manolo Bellotto, Ph.D., Gain Therapeutics<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EOvvvj1BsSxYT8f076-kPqdLGQ_cTMTZGU8IYeEvQoohVE352tmMJQ84lSQWb_yH1ksKryF3UEnPsB0f4Q9JhP9fc4jnayEixFxKXI8gzkHLm4Y_z2p16T-ieZqMnxp5nAjHJH4c6aB4CEd-_611x-elNueos7UfZm4g4YKtHX4jKdyA8V8WfN0hXmCSRgcHm7z-2Wq3dO2mgvvoe74E6tv_KcNgmzuNcuC9HXYrnywK3RVEhx0y1lkQ3ESzL10b\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>2023 Lysosomal Diseases Gordon Research Conference: Connecting Function to Pathophysiology for Innovative Therapies<br \/><\/strong><br \/>\n        <\/a><br \/>\n        <strong>Website: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YcHnK2BECU5ZPuwsMTGYJbsCgdEsaBjqa0T6g8NZmkfLvfW1tKg35G56T3rl9dsuAuzc-BY7NYNogxU2M3wuia8qwUj_s6_r9p4soQYPMVCjecJ5_ABcxqFO8sFYiG9k8vuvVhy9TrEC76ZFxpgKbVntcg6_W9YtDktsLEkhCa-WjaiSEYBcdkY1Hk77kqDN\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.grc.org\/lysosomal-diseases-conference\/2023\/<\/a><br \/>\n        <br \/>\n        <strong>Date\/Time:<\/strong> May 14 &#8211; 19, 2023<br \/><strong>Location:<\/strong> Castelldefels, Spain<br \/><strong>Presenter: <\/strong>Manolo Bellotto, Ph.D., Gain Therapeutics<\/p>\n<p align=\"justify\">Additional details on abstracts and posters will be posted when they become available under the Events section of the Gain Website.<\/p>\n<p align=\"justify\">\n        <strong>About Gain Therapeutics, Inc. <\/strong>\n      <\/p>\n<p align=\"justify\">Gain Therapeutics, Inc. is transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments to address unmet medical needs. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition, and allosteric activation. Gain\u2019s pipeline spans neurodegenerative diseases, lysosomal storage disorders (LSDs), metabolic disorders, as well as other diseases that can be targeted through protein degradation, such as oncology. Gain\u2019s lead program in Parkinson\u2019s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) and The Silverstein Foundation for Parkinson\u2019s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YcHnK2BECU5ZPuwsMTGYJfghHEeK78F2KjXoXOVI4DbTvGMNwa3LlXEltQFGuQ5LlMchnOm7wqtagG1ftUJ3Sm-99ymBJOw8mdO6sluZjRcRYv2UaS_qdfQnQig1FvZV\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.gaintherapeutics.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Cautionary Note Regarding Forward-Looking Statements <\/em><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <em>This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;goal, &#8221; &#8220;intend,&#8221; &#8220;seek, &#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of these terms and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements, other than historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding: the development of the Company\u2019s current or future product candidates; expectations regarding timing for reporting data from ongoing preclinical studies or the initiation of future clinical trials, including the timing for completion of IND-enabling toxicology studies and submission of the dossier requirement for commencement of a Phase 1 clinical program for GT-02287 for GBA1 Parkinson\u2019s disease and the potential therapeutic and clinical benefits of the Company\u2019s product candidates; the selection and development, and timing thereof, of future programs, or any potential business development opportunities for product candidates; the Company\u2019s financial position and ability to execute on the next phase of its strategy; and the Company\u2019s anticipated cash runway guidance, including the ability for the Company\u2019s current and projected cash to allow the Company to meet value inflection points. Each of these forward-looking statements involves risks and uncertainties that could cause the Company\u2019s preclinical and future clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. These statements are not historical facts but instead represent the Company&#8217;s belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company&#8217;s control.<\/em><br \/>\n        <em>Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic and other global and macroeconomic conditions on the Company\u2019s business; clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company\u2019s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the sections titled \u201cRisk Factors,\u201d \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d and elsewhere in the Company\u2019s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission from time to time. New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements. All information in this press release is as of the date of the release, and we are under no duty to update this information after the date of this release, except as required by law. You should not rely on it as representing our views as of any date subsequent to the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong>Investor &amp; Media Contact:<\/strong><br \/>\n        <br \/>Argot Partners<br \/>(212) 600-1902<br \/>Gain@argotpartners.com<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWExNmU1MDktNjBhYi00MzEyLWE2NTYtNjQ3Y2IzODdkZWZlLTEyMjA1ODM=\/tiny\/Gain-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Gain to present new preclinical data on its lead programs in GBA1-related diseases BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present new preclinical data at the following upcoming scientific and medical meetings. \u201cThe body of data that has been generated over the past year in our lead program for GBA1-related diseases is impressive as it demonstrates the mechanism of action and the potentially disease-modifying effect in multiple relevant in vitro and in vivo models,\u201d said Matthias Alder, CEO of Gain Therapeutics. \u201cBased &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728180","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gain to present new preclinical data on its lead programs in GBA1-related diseases BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present new preclinical data at the following upcoming scientific and medical meetings. \u201cThe body of data that has been generated over the past year in our lead program for GBA1-related diseases is impressive as it demonstrates the mechanism of action and the potentially disease-modifying effect in multiple relevant in vitro and in vivo models,\u201d said Matthias Alder, CEO of Gain Therapeutics. \u201cBased &hellip; Continue reading &quot;Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-02T13:17:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences\",\"datePublished\":\"2023-02-02T13:17:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/\"},\"wordCount\":1005,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/\",\"name\":\"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=\",\"datePublished\":\"2023-02-02T13:17:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences - Market Newsdesk","og_description":"Gain to present new preclinical data on its lead programs in GBA1-related diseases BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present new preclinical data at the following upcoming scientific and medical meetings. \u201cThe body of data that has been generated over the past year in our lead program for GBA1-related diseases is impressive as it demonstrates the mechanism of action and the potentially disease-modifying effect in multiple relevant in vitro and in vivo models,\u201d said Matthias Alder, CEO of Gain Therapeutics. \u201cBased &hellip; Continue reading \"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-02T13:17:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences","datePublished":"2023-02-02T13:17:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/"},"wordCount":1005,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/","name":"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=","datePublished":"2023-02-02T13:17:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTYzMiM1Mzg3NTU1IzIyMDkwMzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-scientific-and-medical-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728180"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728180\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}